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ABSTRACT
Background    Maspin is known to be a tumor suppres-
sor protein and its prognostic significance in patients 
with several types of cancer has been reported. To date, 
however, no study has focused on the association be-
tween maspin expression and the prognosis of patients 
with adenocarcinoma of the uterine cervix. We explored 
the prognostic value of maspin expression with particu-
lar reference to its subcellular localization in patients 
with adenocarcinoma of the uterine cervix.
Methods    Paraffin-embedded tissue samples from 46 
patients diagnosed as adenocarcinoma of the uterine 
cervix were immunohistochemically analyzed using an 
antibody for maspin. The patients were followed up for 3 
to 165 months (median: 64.2 months) and the prognostic 
value was evaluated by the log-rank test and the Cox re-
gression hazard model. 
Results    A sample was considered maspin-positive if 
maspin was expressed in only the cytoplasm; 69.6% (32 
cases) of the specimens were maspin-positive, and there 
was significant correlation between positivity and recur-
rence (P = 0.022). Maspin-positive patients had both 
shorter disease free survival and shorter overall survival 
by the log-rank test (P = 0.023, P = 0.043, respectively). 
By Cox’s multivariate analysis, the International Federa-
tion of Obstetrics and Gynecology (FIGO) status was 
the only independent prognostic factor for disease free 
survival and overall survival in patients with adenocar-
cinoma of the uterine cervix.
Conclusion    This is the first report to reveal an asso-
ciation between cytoplasmic maspin expression and the 
prognosis of patients with adenocarcinoma of the uterine 
cervix. Although further studies with a larger series of 
patients and a longer follow up period are necessary, the 
present results suggest that cytoplasmic maspin expres-
sion could be an indicator of unfavorable prognosis in 
patients with adenocarcinoma of the uterine cervix. 
Key words    adenocarcinoma; immunohistochemistry; 
maspin; uterine cervix
Adenocarcinoma of the uterine cervix is a relatively 
uncommon histological subtype of uterine cancer com-
prising 10–20% of all cervical cancer cases.1 Although 
squamous cell carcinoma (SCC) of the uterine cervix 
has declined markedly in developed countries, both the 
relative and absolute incidences of adenocarcinoma of 
the uterine cervix have increased over the past four de-
cades.1, 2 The majority of reports have shown that adeno-
carcinoma of the uterine cervix carries a worse progno-
sis than SCC in 5-year overall survival rates, and that its 
survival rates are significantly lower than SCC’s in each 
tumor stage.3–5 Differences have also been reported be-
tween SCC and adenocarcinoma of the uterine cervix in 
the pattern of dissemination, recurrences and response 
to chemotherapy.3 The important prognostic factors have 
been considered to be the International Federation of 
Obstetrics and Gynecology (FIGO) stage, tumor size 
and the occurrence of lymph nodes metastasis. However, 
the search for another predictive factor for adenocarci-
noma of the uterine cervix may be important for decid-
ing on a therapeutic strategy. Maspin, a member of the 
serine protease inhibitor (serpin) family, was originally 
detected in normal breast epithelial cells.6 Maspin ex-
pression was previously shown to be down-regulated 
as breast epithelial cells progressed to a higher grade of 
breast tumor and to be lost in metastasis and it has been 
shown to have tumor suppressor activity attributable to 
the inhibition of breast cancer cell motility, invasion and 
metastasis.7 Although the precise biochemical pathways 
leading to these biological endpoints remains to be elu-
cidated, many reports describe the association between 
maspin expression and clinicopathological factors in 
many types of cancer.8 We have also reported on as-
sociations between maspin expression and clinicopatho-
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logical factors in several types of cancer such as breast 
cancer,9–11 colorectal cancer,12 endometrioid endometrial 
carcinoma,13 ovarian mucinous borderline tumor,14 lung 
adenocarcinoma  and soft tissue sarcoma;15, 16 and we 
have suggested that cytoplasmic maspin expression may 
be an indicator of poor prognosis. To our knowledge, 
this is the first report to investigate the association be-
tween maspin expression and the prognosis of patients 
with adenocarcinoma of the uterine cervix. The aim of 
this study was to clarify whether cytoplasmic expression 
of maspin could be a predictive factor for patients with 
adenocarcinoma of the uterine cervix as well as other 
types of cancers.
MATERIALS AND METHODS
Tissue specimens
This study enrolled a total of 46 consecutive patients 
with adenocarcinoma of the uterine cervix diagnosed at 
the Department of Pathology Tottori University Hospital 
between 1999 and 2010. The median follow up period 
was 64.2 months (range: 3–165 months). Since a con-
siderable number of patients had received neoadjuvant 
chemotherapy, radiotherapy or both before tumor resec-
tion, we selected tissues mainly from biopsy specimens 
to prevent therapy-related changes from disturbing his-
tological or immunohistochemical assessment. The pa-
tients’ clinicopathological data were retrieved from the 
hospital’s computerized medical records system. Each 
histological diagnosis was re-evaluated and established 
according to the World Health Organization classifica-
tion17 by experienced pathologists (K.N. and Y.U.). Most 
patients underwent surgical treatments including total 
hysterectomy with lymph node dissection (35 cases), 
radical trachelectomy (3 cases), and simple hysterec-
tomy (1 case); the inoperable patients received either 
chemoradiotherapy (5 cases) or chemotherapy only (2 
cases). Written informed consent was obtained from all 
patients, and the study was performed with the approval 
of the Ethics Committee of the Faculty of Medicine, 
Tottori University (No. 1558).
Immunohistochemical procedures
All specimens were fixed in 10% neutrally buffered 
formalin and embedded in paraffin. A representative 
block from each case containing an adequate amount 
of tumor tissue was selected. After the sections (4 μm 
thick) were deparaffinized and endogenous peroxidase 
activity was blocked, they were pretreated in citrate buf-
fer (0.01 M, pH 6.0) using a microwave oven (RE-DD6-
S; Sharp, Osaka, Japan) for 20 minutes. After cooling to 
room temperature, the sections were incubated at 4 ˚C 
overnight with monoclonal anti-human maspin antibody 
(clone EAW24; diluted 1:50; Leica Biosystems, New-
castle, UK). The sections were incubated with biotinyl-
ated anti-mouse IgG antibody (BA-2000; diluted 1:150; 
Vector Laboratories, Burlingame, VT) for 20 minutes, 
followed by streptavidin biotinylated-HRP conjugate (di-
luted 1:150; Invitrogen, Camarillo, CA) for 20 minutes. 
The sections were then incubated with 3,3’-Diaminoben-
zidine (DAB) solution (Liquid DAB+ Substrate, Imid-
azole-HCl buffer, pH 7.5, containing hydrogen peroxide 
and an anti-microbial agent; Dako, Glostrup, Denmark) 
for 4 minutes, and finally were counterstained with he-
matoxylin. 
Immunohistochemical evaluation 
To evaluate maspin expression status, the sections were 
divided into two groups: maspin-positive and -negative. 
Specimens were considered maspin-positive if staining 
occurred only in the cytoplasm with a staining area of 
> 10% of the whole tumor for each section irrespective 
of staining intensity. The remaining specimens were 
considered maspin-negative. These evaluations were 
performed independently by two authors (K.N. and Y.U.), 
who were blinded to the patients’ outcome data. Nor-
mal squamous epithelium served as an internal positive 
control if it was present in the same specimen. Myoepi-
thelial cells in normal breast tissue specimens were also 
used as positive controls.
Statistical analysis
All statistical analyses were performed using the Statis-
tical Package for Social Sciences version 21 (IBM SPSS 
Statistics; IBM, Armonk, NY). The association between 
maspin status and clinicopathological parameters was 
evaluated by non-parametric tests. The chi-square test 
was used when there were two categorical variables of 
interest and the Kruskal-Wallis test when there were 
three or more variables. Survival curves were calculated 
using the Kaplan-Meier method and compared by log-
rank test. The Cox proportional hazard regression model 
was used to analyze the independence of each parameter 
of disease free survival (DFS) or overall survival (OS). 
RESULTS 
Clinicopathological features
The clinicopathological profiles of the 46 patients are 
summarized in Table 1. The age distribution was 22–74 
years (median: 50.0 years). Thirty-three cases were at 
FIGO Stage I/II and 13 cases were at Stage III/IV. In 
23 cases (50%) the tumor was larger than 40mm, and in 
10 cases (21.7%) lymph node metastasis was recognized 
either at operation or at first radiographic examination. 
Nineteen cases (41.3%) had recurrent diseases: 6 distal 
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metastasis (lung: 4, brain: 2, liver: 1, bone: 1), 11 local 
recurrences and 2 peritoneal disseminations. 
Table 1. Clinicopathologic characteristics of patients 
with adenocarcinoma of the uterine cervix
　 n %
Age (years old)
 < 30 1 2.2 
 30–39 8 17.4
 40–49 13 28.3
 50–59 14 30.4
 60–69 8 17.4
 ≥ 70 2 4.3
Recurrence
 None 27 58.7
 Local recurrence 11 17.4
 Distant metastasis 6 19.6
 Peritoneal dissemination 2 4.3
FIGO stage
 IB 22 47.8
 IIA 2 4.3
 IIB 9 19.6
 IIIA 1 2.2
 IIIB 7 15.2
 IV 5 10.9
Tumor size
 < 40mm 21 45.7
 ≥ 40mm 23 50.0
Lymph node metastasis
 Negative 30 65.2
 Positive 10 21.7
 Unknown 6 13.0
Histological subtype
 Mucinous adenocarcinoma 20 43.4
  Endocervical type 17 37.0
  Intestinal type 3 6.5
 Endometrioid adenocarcinoma 16 34.8
 Others 5 10.8
 Adenosquamous carcinoma 5 10.8
Treatment procedure
 Resection only 13 28.3
 Resection with neoadjuvant chemotherapy 13 28.3
 Resection with adjuvant therapy only 13 28.3
 Chemo-radiation therapy only 5 10.9
 Chemotherapy only 2 4.3
FIGO, The International Federation of Gynecology and Obstet-
rics.
Immunohistochemical findings and correlation 
with clinicopathological factors 
Representative staining patterns of maspin expression 
are shown in Fig. 1. Subcellular localization was clas-
sified into three categories: cytoplasmic staining only 
(32 cases, 69.6%), pancellular staining (both nuclear and 
cytoplasm; 4 cases, 8.7%), nuclear staining only (4 cases, 
8.7%) and no staining (6 cases, 13%). The latter three 
patterns were judged as maspin-negative. Maspin-posi-
tive status was significantly correlated with recurrence (P 
= 0.022) and slightly correlated with the non-mucinous 
subtype (P = 0.042) (Table 2).
Table 2. Associations between maspin expression and 
clinicopathological factors in adenocarcinoma of the 
uterine cervix
Maspin expression
Positive Negative P-value
FIGO stage
 I and II 20 13 0.072
 III and IV 12 1
Tumor size
 < 40mm 13 8 0.179
 ≥ 40mm 19 4
Lymph node metastasis
 Present 19 11 0.279
 Absent 11 2
Histological subtype
 Mucinous 10 10 0.042*
 Endometrioid 13 3
 Others 9 1
Recurrence
 Present 17 2 0.022*
 Absent 15 12
*P < 0.05. FIGO, The International Federation of Gynecology and 
Obstetrics.
Survival analysis
During the follow up period, 19 patients experienced 
recurrent disease and 18 patients died of the disease. In 
the log-rank test, maspin-positive patients showed sig-
nificantly shorter DFS (P = 0.023) and OS (P = 0.043) 
(Fig. 2). The 5 years DFS rates of the maspin-positive 
and -negative groups were 45.5% (95% CI 0.27–0.64) 
and 85.1% (95% CI 0.66–1.04), respectively. The 5 years 
OS rates of the maspin-positive and -negative groups 
were 54.0% (95% CI 0.36–0.72) and 82.1% (95% CI 
0.59–1.07), respectively. There were significant dif-
ferences in DFS and OS in the Kaplan-Meier curves 
according to FIGO stage (P < 0.001, P < 0.001, respec-
tively) and lymph node metastasis (P = 0.002, P < 0.001, 
respectively). There was significant difference of OS in 
Kaplan-Meier curves according to tumor size (P = 0.005). 
According to Cox multivariate analysis, advanced FIGO 
stage was the only independent prognostic factor for 
both DFS (P = 0.001) and OS (P = 0.002) (Table 3).
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Fig. 1. Representative immunoreactivity for maspin in formalin-fixed paraffin-embedded adenocarcinoma tissues of the uterine cervix.
A: Normal squamous epithelium showed both cytoplasmic and nuclear staining, while normal columnar epithelium was not stained at the 
squamo-columnar junction.
B: Mucinous adenocarcinoma showing only cytoplasmic staining for maspin. 
C: Mucinous adenocarcinoma showing both cytoplasmic and nuclear staining for maspin. 
D: Mucinous adenocarcinoma showing only nuclear staining for maspin.
Fig. 2. Disease-free survival (left) and overall survival (right) curves of 46 patients with uterine cervical adenocarcinoma according 
to maspin positivity status.
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Table 3. Multivariate analysis of clinicopathological factors for disease-free survival and overall survival
Disease-free survival Overall survival
HR 95% Cl P-value HR 95% Cl P-value
Maspin 
 Positive vs. negative 2.733 0.609–12.262 0.189 3.505 0.684–17.953 0.132
FIGO stage
 I,II vs. III, IV 0.070 0.015–0.324 0.001* 0.101 0.024–0.419 0.002*
Tumor size
 < 40mm vs. ≥ 40mm 0.958 0.345–2.665 0.935 2.350 0.693–7.968 0.170
Lymph node metastasis
 Positive vs. negative 0.823 0.215–3.142 0.775 2.117 0.573–7.823 0.261
* P < 0.05. CI, confidence interval; FIGO, The International Federation of Gynecology and Obstetrics; HR, hazard ratio.
DISCUSSION
It has been reported that adenocarcinoma of the uterine 
cervix is clearly different from SCC based on its epide-
miology, molecular pathogenesis and clinical behavior, 
including the response to chemotherapy and the patterns 
of recurrence.3 It has also been reported that adenocar-
cinoma is more likely to involve both lymph node and 
distant metastasis compared to SCC resulting in a worse 
prognosis.18, 19 The main prognostic factors are con-
sidered to be the presence of lymph nodes metastasis, 
tumor size and FIGO stage. However, few molecular 
alterations of adenocarcinoma of the uterine cervix 
have been reported, in contrast to the case with SCC. 
Therefore, it will be important to explore new molecular 
markers. The p53 gene is a candidate molecular marker 
for adenocarcinoma of the uterine cervix. It has been 
reported that nucleotide changes in the p53 gene were 
significantly more frequent in adenocarcinoma of the 
uterine cervix than in SCC, and the highest incidence of 
p53 gene mutations was observed in adenocarcinoma of 
the uterine cervix from Asia and Europe.20 On the other 
hand, maspin is a member of the serpin family of prote-
ase inhibitors and was originally thought to be a tumor 
suppressor due to its ability to inhibit invasion, motil-
ity, lymphangiogenesis and metastasis of mammary 
tumors.6, 21 However, the loss of maspin expression in 
several cancers such as pancreatic, colorectal and ovar-
ian cancers cannot typically be observed because of the 
lack of maspin expression in the corresponding normal 
tissue. The most compelling data regarding the clinical 
significance of maspin in cancer progression and metas-
tasis emerged from survival studies of cancer patients. 
Although the original studies revealed the association 
of reduced maspin expression with cancer progression 
and worse prognosis, it has been demonstrated that this 
correlation was far more complex than originally sus-
pected.8 Factors contributing to this complexity include 
differences in cancer type (for example, adenocarcinoma 
vs. SCC), cut-off values of positive criteria, antibodies 
used, methods of detection used, and subcellular maspin 
distribution. Recent evidence indicates that nuclear 
localization of maspin in cancer cells is necessary for 
its tumor suppressor activity and that, when excluded 
from the nucleus, maspin exhibited no tumor suppressor 
activity.22, 23 These results suggest that maspin local-
ized in the nucleus may result in better prognosis, while 
cytoplasmic maspin accumulation may result in an unfa-
vorable prognosis, which is consistent with our previous 
reports suggesting that cytoplasmic maspin could be 
a predictor of worse prognosis in several types of can-
cers.9–16 In turn, it has been reported that p53 activated 
the maspin promoter by binding directly to the p53 
consensus-binding site present in the maspin promoter, 
suggesting the close association between maspin and 
the p53 gene.24 As nucleotide changes in the p53 gene 
were significantly more frequent in adenocarcinoma of 
the uterine cervix than in SCC,20 further investigation 
concerning the gene or protein alteration of both maspin 
and p53 may be intriguing. Although the present study 
has the limitations of a small number of patients and a 
retrospective nature, we for the first time suggested that 
cytoplasmic maspin expression might be a candidate 
molecular marker of progression in adenocarcinoma of 
the uterine cervix. 
 In conclusion, to our knowledge, this is the first in-
vestigation of the association between maspin expression 
and the prognosis of patients with adenocarcinoma of 
the uterine cervix. Although further studies with a larger 
series of patients and a longer follow-up period should 
be undertaken, the present study suggests the potential 
usefulness of cytoplasmic maspin expression as a prog-
nostic factor for patients with adenocarcinoma of the 
uterine cervix. The immunohistochemical detection of 
maspin could be a new marker of aggressive behavior in 
patients with adenocarcinoma of the uterine cervix.
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